At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 9 enrolled
Drug / intervention
Ketaminedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Systematic Investigation of Neurophysiological Correlates of Low Dose Intravenous Ketamine in Treatment Resistant Depression Patients
The University of Texas Health Science Center, Houston·interventional·Posted Oct 17, 2016·Updated Jan 13, 2022
In Brief
A Phase 2 clinical trial evaluating Ketamine for Treatment Resistant Depression. Completed, enrolled 9 participants across 1 site.
Detailed Summary
The primary goal of the project is to study the effect of Ketamine on cortical neurophysiological function in TRD patients. The proposal employs robust and non-invasive neurophysiological techniques TMS and EEG to investigate the cortical excitability and oscillatory activity in patients with treatment resistant depression.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTreatment Resistant Depression
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartOct 2016
First PostedOct 2016
Primary CompletionAug 2017
TodayJul 2026
First PostedOct 17, 2016
Enrollment StartOct 14, 2016
Primary CompletionAug 16, 2017
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 9.7 years ago
Interventions
Ketaminedrug
Ketamine Hydrochloride Injection